OTCMKTS:INTI Inhibitor Therapeutics (INTI) Stock Price, News & Analysis $0.08 0.00 (0.00%) As of 11/13/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsNews and TrendsSEC Filings About Inhibitor Therapeutics Stock (OTCMKTS:INTI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Inhibitor Therapeutics alerts:Sign Up Key Stats Today's Range$0.08▼$0.0850-Day Range$0.06▼$0.1152-Week Range$0.04▼$0.12Volume1 shsAverage Volume14,653 shsMarket Capitalization$13.90 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Inhibitor Therapeutics is a development-stage pharmaceutical company focused on investigating treatments for cancer. Its work includes repurposing itraconazole, an established antifungal medicine, for potential use in cancer treatment. The company has pursued development of itraconazole for prostate cancer and basal cell carcinoma. These are investigational uses; itraconazole’s existing approval as an antifungal does not mean it is approved to treat cancer.AI Generated. May Contain Errors. Read More Inhibitor Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks3rd Percentile Overall ScoreINTI MarketRank™: 0.130705944795 of 5 starsInhibitor Therapeutics scored higher than 3% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Inhibitor Therapeutics. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Inhibitor Therapeutics is -8.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Inhibitor Therapeutics is -8.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.00% of the float of Inhibitor Therapeutics has been sold short.Short Interest Ratio / Days to CoverInhibitor Therapeutics has a short interest ratio ("days to cover") of 0.01, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Inhibitor Therapeutics has recently increased by 100.00%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInhibitor Therapeutics does not currently pay a dividend.Dividend GrowthInhibitor Therapeutics does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A News SentimentInhibitor Therapeutics has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Inhibitor Therapeutics this week, compared to 0 articles on an average week. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Inhibitor Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders27.80% of the stock of Inhibitor Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsInhibitor Therapeutics has minimal institutional ownership at this time.Read more about Inhibitor Therapeutics' insider trading history. Receive INTI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inhibitor Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. INTI Stock News HeadlinesInhibitor Therapeutics Highlights Key Developments and Reminds Stockholders of September 15 Annual MeetingSeptember 8, 2026 | globenewswire.comCheckpoint Inhibitor Refractory Cancer Market Outlook is Predicted to Improve by 2036, Biopharma Companies Advance Novel Immuno-Oncology Candidates | DelveInsightAugust 19, 2026 | finance.yahoo.comMy $247 scanner for $7Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment that covers a full year, with no subscription and no re-bills. Every night after the close, the scanner screens nearly a thousand of America's biggest stocks. It returns a short list of qualifying setups with the exact buy price next to each one. There's nothing to install. If you decide it's not for you, you get the $7 back and keep the scanner for the year.November 16 at 1:00 AM | Profits Run (Ad)Blacksmith Medicines Announces Publication in Journal of Medicinal Chemistry Highlighting Discovery of a Non-Hydroxamate LpxC InhibitorAugust 5, 2026 | finance.yahoo.comInhibitor Therapeutics Advances Gorlin Syndrome Itraconazole ProgramJune 18, 2026 | theglobeandmail.comInhibitor Therapeutics Sues Investor Over Failed Financing DealApril 1, 2026 | tipranks.comInhibitor Therapeutics Provides Clinical, Formulation and IP Update on Itraconazole Program for Gorlin SyndromeMarch 31, 2026 | markets.businessinsider.comInhibitor Therapeutics Provides Clinical, Formulation and IP Update on Itraconazole Program for Gorlin SyndromeMarch 31, 2026 | globenewswire.comSee More Headlines INTI Stock Analysis - Frequently Asked Questions How have INTI shares performed this year? Inhibitor Therapeutics' stock was trading at $0.0450 at the start of the year. Since then, INTI stock has increased by 77.8% and is now trading at $0.08. How were Inhibitor Therapeutics' earnings last quarter? Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) posted its quarterly earnings results on Wednesday, March, 25th. The company reported ($0.01) EPS for the quarter. How do I buy shares of Inhibitor Therapeutics? Shares of INTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today11/16/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:INTI CIK1042418 Webwww.inhibitortx.com Phone(888) 841-6811Fax813-527-0500Employees1Year Founded1992Profitability EPS (Trailing Twelve Months)($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$3.30 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-171.44% Debt Debt-to-Equity RatioN/A Current Ratio3.36 Quick Ratio3.36 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.01) per share Price / Book-8.00Miscellaneous Outstanding Shares173,790,000Free Float125,478,000Market Cap$13.90 million OptionableNot Optionable Beta-0.73 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (OTCMKTS:INTI) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersA $247 tool for $7Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full ...Profits Run | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredYour Copy is on Hold (Claim it now)James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on E...Paradigm Press | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredSmall-Cap SMX is Taking its Technology into Multiple Trillion-Dollar Industries!SMX (NASDAQ: SMX) uses proprietary molecular-marking technology and a Digital Material Passport platform to gi...Smallcaps Daily | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibitor Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibitor Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.